Intellia is a pioneer in the development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies towards the clinic.

Our company’s unique strengths include our modular lipid nanoparticle delivery system and our determined focus on product development.

Programs & Pipeline

Each one of us together for patients

We believe our modular approach to selecting our in vivo and ex vivo programs positions us to build a full-spectrum genome editing company, with a pipeline across a range of indications. This approach enables us to generate a wealth of data that opens the potential therapeutic applications of the CRISPR/Cas9 technology across a broad range of diseases.

Join Us.
See how you can change life stories with genome editing
Follow Us on Social Media
September 16, 2021

Today, Intellia announced the @US_FDA accepted its Investigational New Drug Application to initiate the first clinical trial for NTLA-5001, our #CRISPR/Cas9 #celltherapy candidate for #acutemyeloidleukemia. Full details here: https://t.co/8cWBFkUEvu https://t.co/uss5LspIQy

September 15, 2021

We’re kicking off the first episode of our podcast with our CSO, @LauraSeppLore, who will discuss being inspired by others and how to face challenges in your career head-on. Available now: https://t.co/AZVrJQElKT #InsideIntellia #OneIntellia https://t.co/YDN9DfPfMD